These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 21293833)

  • 1. Cutaneous side-effects of EGFR inhibitors and their management.
    Ehmann LM; Ruzicka T; Wollenberg A
    Skin Therapy Lett; 2011 Jan; 16(1):1-3. PubMed ID: 21293833
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Escalating therapy of cutaneous side effects of EGFR inhibitors: experience of German reference centers.
    Homey B; Gerber PA; Wollenberg A; Dirschka T; Hassel JC; Bölke E; Hauschild A; Gutzmer R
    J Dtsch Dermatol Ges; 2012 Aug; 10(8):559-63. PubMed ID: 22672156
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Management of cutaneous side-effects of cetuximab therapy in patients with metastatic colorectal cancer.
    Ocvirk J; Cencelj S
    J Eur Acad Dermatol Venereol; 2010 Apr; 24(4):453-9. PubMed ID: 19793151
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Classification and management of skin, hair, nail and mucosal side-effects of epidermal growth factor receptor (EGFR) inhibitors.
    Galimont-Collen AF; Vos LE; Lavrijsen AP; Ouwerkerk J; Gelderblom H
    Eur J Cancer; 2007 Mar; 43(5):845-51. PubMed ID: 17289377
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Cutaneous side effects of EGFR inhibitors--appearance and management].
    Wollenberg A; Kroth J; Hauschild A; Dirschka T
    Dtsch Med Wochenschr; 2010 Jan; 135(4):149-54. PubMed ID: 20101558
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acneiform eruptions induced by epidermal growth factor receptor inhibitors: treatment with oral isotretinoin.
    Requena C; Llombart B; Sanmartín O
    Cutis; 2012 Aug; 90(2):77-80. PubMed ID: 22988651
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Cutaneous effects related to the use of tyrosine kinase inhibitors].
    Mateus C
    Rev Pneumol Clin; 2007 Jan; 63(1 Pt 2):2S16-7. PubMed ID: 17242640
    [No Abstract]   [Full Text] [Related]  

  • 8. [Skin eruptions as an adverse reaction to epidermal growth-factor receptor inhibitors].
    Tjin-A-ton ML; van Montfrans C; Koldenhof JJ; Sigurdsson V; Voest EE; Witteveen PO
    Ned Tijdschr Geneeskd; 2007 Apr; 151(17):945-52. PubMed ID: 17520845
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Management of the cutaneous side effects of therapeutic epidermal growth factor receptor inhibition.
    Reck M; Gutzmer R
    Onkologie; 2010; 33(8-9):470-9. PubMed ID: 20838065
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cutaneous side effects of epidermal growth factor receptor inhibitors: clinical presentation, pathogenesis, and management.
    Hu JC; Sadeghi P; Pinter-Brown LC; Yashar S; Chiu MW
    J Am Acad Dermatol; 2007 Feb; 56(2):317-26. PubMed ID: 17141360
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cutaneous adverse effects during therapy with an epidermal growth factor receptor (EGFR) inhibitor.
    Santoro F; Cozzani E; Parodi A
    J Dermatolog Treat; 2006; 17(3):160-1. PubMed ID: 16854757
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of epidermal growth factor receptor inhibitor-induced acneiform eruption with topical recombinant human epidermal growth factor.
    Shin JU; Park JH; Cho BC; Lee JH
    Dermatology; 2012; 225(2):135-40. PubMed ID: 23006507
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Persistent hair growth during treatment with the EGFR inhibitor erlotinib.
    Alexandrescu DT; Kauffman CL; Dasanu CA
    Dermatol Online J; 2009 Mar; 15(3):4. PubMed ID: 19379648
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A tool for scoring of acneiform skin eruptions induced by EGF receptor inhibition.
    Wollenberg A; Moosmann N; Klein E; Katzer K
    Exp Dermatol; 2008 Sep; 17(9):790-2. PubMed ID: 18503553
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of treatment with a colloidal oatmeal lotion on the acneform eruption induced by epidermal growth factor receptor and multiple tyrosine-kinase inhibitors.
    Alexandrescu DT; Vaillant JG; Dasanu CA
    Clin Exp Dermatol; 2007 Jan; 32(1):71-4. PubMed ID: 17034418
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cutaneous reactions to epidermal growth factor receptor inhibitors.
    Pomerantz RG; Mirvish ED; Geskin LJ
    J Drugs Dermatol; 2010 Oct; 9(10):1229-34. PubMed ID: 20941947
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Description and management of cutaneous side effects during cetuximab or erlotinib treatments: a prospective study of 30 patients.
    Roé E; García Muret MP; Marcuello E; Capdevila J; Pallarés C; Alomar A
    J Am Acad Dermatol; 2006 Sep; 55(3):429-37. PubMed ID: 16908348
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HER1/EGFR inhibitor-associated rash: future directions for management and investigation outcomes from the HER1/EGFR inhibitor rash management forum.
    Pérez-Soler R; Delord JP; Halpern A; Kelly K; Krueger J; Sureda BM; von Pawel J; Temel J; Siena S; Soulières D; Saltz L; Leyden J
    Oncologist; 2005 May; 10(5):345-56. PubMed ID: 15851793
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cutaneous drug eruptions associated with the use of new oncological drugs.
    Belloni B; Schönewolf N; Rozati S; Goldinger SM; Dummer R
    Chem Immunol Allergy; 2012; 97():191-202. PubMed ID: 22613863
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Skin Manifestations of Targeted Antineoplastic Therapy.
    Sanmartín O
    Curr Probl Dermatol; 2018; 53():93-104. PubMed ID: 29131041
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.